Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05849077 · ClinicalTrials.gov registry record · NA

Optimization of Saturation Targets And Resuscitation Trial (OptiSTART)

A NA study of Bronchopulmonary Dysplasia and Intraventricular Hemorrhage, sponsored by University of Texas Southwestern Medical Center.

Recruiting
Registry status
NA
Development phase
700
Enrollment target
1
Study location

NCT05849077: Recruiting NA study of Bronchopulmonary Dysplasia and Intraventricular Hemorrhage, sponsored by University of Texas Southwestern Medical Center.

NCT05849077 is a NA study of Bronchopulmonary Dysplasia and Intraventricular Hemorrhage that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 700 participants, above the 212-participant average among 29 other Bronchopulmonary Dysplasia trials with a reported enrollment target (230% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05849077, a NA study of Bronchopulmonary Dysplasia and Intraventricular Hemorrhage, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.

RECRUITING
Registry status
NA
Development phase
700 participants
Enrollment target
1
Study location

Study Summary

This study is designed to answer one of the fundamental gaps in knowledge in the resuscitation of preterm infants at birth: What is the optimal target oxygen saturation (SpO2) range that increases survival without long-term morbidities? Oxygen (O2) is routinely used for the stabilization of preterm infants in the delivery room (DR), but its use is linked with mortality and several morbidities including bronchopulmonary dysplasia (BPD). To balance the need to give sufficient O2 to correct hypoxia and avoid excess O2, the neonatal resuscitation program (NRP) recommends initiating preterm resuscitation with low (≤ 30%) inspired O2 concentration (FiO2) and subsequent titration to achieve a specified target SpO2 range. These SpO2 targets are based on approximated 50th percentile SpO2 (Sat50) observed in healthy term infants. However, the optimal SpO2 targets remain undefined in the preterm infants. Recent data suggest that the current SpO2 targets (Sat50) may be too low. The investigators plan to conduct a multicenter RCT of Sat75 versus Sat50 powered for survival without BPD. The investigators will randomize 700 infants, 23 0/7- 30 6/7 weeks' GA, to 75th percentile SpO2 goals (Sat75, Intervention) or 50th percentile SpO2 goals (Sat50, control). Except for the SpO2 targets, all resuscitations will follow NRP guidelines including an initial FiO2 of 0.3. In Aim 1, the investigators will determine whether targeting Sat75 compared to Sat50 increases survival without lung disease (BPD). In addition, the investigators will compare the rates of other major morbidities such as IVH. In Aim 2, the investigators will determine whether targeting Sat75 compared to Sat50 increases survival without neurodevelopmental impairment at 2 years of age. In Aim 3, the investigators will determine whether targeting Sat75 compared to Sat50 decreases oxidative stress.

Primary Outcome

The primary outcome for this trial is survival without BPD at 36 weeks' PMA. Both components, death and BPD, will also be reported separately. Neonatal mortality during the NICU stay, the postnatal day at the time of mortality and the primary cause of mortality will be recorded. BPD will be defined as the need for any form of positive airway pressure support or supplemental O2 at 36 weeks' PMA.BPD will be graded as mild, moderate and severe as per the NICHD consensus definition. All eligible inf

Interventions

  • OTHER Sat75
  • OTHER Sat50

Study Locations (1)

Texas

  • University of Texas Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 700 participants
Start Date 2024-02-26
Est. Completion 2029-04-01
Phase NA

What NCT05849077 shows while recruiting

NCT05849077 is an interventional study that assigns participants to a tested intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, above the 212-participant average among 29 other Bronchopulmonary Dysplasia trials with a reported enrollment target (230% higher).

The record links to 4 conditions, with Bronchopulmonary Dysplasia appearing as the primary indexed condition, and to 2 interventions - of which Sat75 is the first listed.

NCT05849077 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT05849077 about?

NCT05849077 is a clinical study titled "Optimization of Saturation Targets And Resuscitation Trial (OptiSTART)". This study is designed to answer one of the fundamental gaps in knowledge in the resuscitation of preterm infants at birth: What is the optimal target oxygen saturation (SpO2) range that increases survival without long-term morbidities? Oxygen (O2) is routinely used for the stabilization of preterm ...

What is the current status of trial NCT05849077?

This trial is currently recruiting. It is a NA study. The enrollment target is 700 participants. The study started on 2024-02-26. Estimated completion is 2029-04-01.

What conditions does trial NCT05849077 study?

This clinical trial studies the following conditions: Bronchopulmonary Dysplasia, Intraventricular Hemorrhage, Premature Infants, Neurodevelopmental Outcomes.

What interventions are being tested in trial NCT05849077?

The interventions under investigation include: Sat75 (OTHER), Sat50 (OTHER).

Who is sponsoring clinical trial NCT05849077?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05849077 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bronchopulmonary Dysplasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05849077's enrollment target sits among peer trials

700 2nd of 29 the highest of 29 other Bronchopulmonary Dysplasia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Bronchopulmonary Dysplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00900419 · 700 participants

    Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers

  • NCT01804686 · 700 participants · Phase 3

    A Long-term Extension Study of PCI-32765 (Ibrutinib)

  • NCT02107989 · 700 participants

    Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database

  • NCT02129543 · 700 participants

    Immune Reconstitution in Stem Cell Transplant Recipients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05849077, the US trial registry maintained by the National Library of Medicine. NCT05849077 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.